Safety of ustekinumab in inflammatory bowel diseases (IBD): pooled safety analysis through 5 years in Crohn's disease (CD) and 2 years in ulcerative colitis (UC)

被引：0
|
作者：
Ghosh, Subrata [1 ]
Ott, Elyssa [2 ]
Gasink, Christopher [2 ]
Miao, Ye [3 ]
Colombel, Jean-Frederic [4 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 36卷
关键词：
ustekinumab; IBD; safety; MACE;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PP-0097
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [21] Risk of ulcerative colitis (UC) and Crohn's disease in offspring of inflammatory bowel disease (IBD) parents: a multicenter Italian study (ig-IBD)
    Bortoli, A
    Ravelli, P
    Paoluzi, P
    Snider, L
    Bertinelli, E
    Peralta, S
    Corbellini, A
    Colombo, E
    Lecis, P
    Bennato, R
    D'Inca, R
    GASTROENTEROLOGY, 2005, 128 (04) : A317 - A317
  • [22] Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn's Disease and Ulcerative Colitis
    Sands, B. E.
    Panaccione, R.
    Danese, S.
    Panes, J.
    Hisamatsu, T.
    D'Haens, G.
    Van Rampelbergh, R.
    Olurinde, M.
    Yee, J.
    Baker, T.
    Yarandi, S.
    Germinaro, M.
    Vetter, M. L.
    Li, H.
    Ballina, M. Rosas
    Allegretti, J.
    Afzali, A.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1206 - i1208
  • [23] Interdisciplinary guidelines: Inflammatory bowel diseases (Crohn's disease, ulcerative colitis)
    Betzler, M
    EFFICIENCY AND ECONOMICS OF CLINICAL CARE AND RESEARCH IN SURGERY, 1997, SUPPL : 109 - 113
  • [24] Interdisciplinary guidelines: Inflammatory bowel diseases - Crohn's disease, ulcerative colitis
    Caspary, WF
    EFFICIENCY AND ECONOMICS OF CLINICAL CARE AND RESEARCH IN SURGERY, 1997, SUPPL : 100 - 108
  • [25] Nonspecific inflammatory bowel disease (ulcerative colitis and Crohn's disease) after 100 years - what next?
    Kirsner, JB
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 31 (08): : 651 - 658
  • [26] Pregnancy outcomes in women exposed to ustekinumab in the Crohn's disease (CD) and ulcerative colitis (UC) clinical trials
    Abraham, Bincy
    Ott, Elyssa
    Busse, Christopher
    Murphy, Conor
    Miller, Lindsay
    Baumgart, Daniel C.
    Scherl, Ellen
    Gasink, Christopher
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 107 - 108
  • [27] REFLORASTATION THERAPY FOR INFLAMMATORY BOWEL-DISEASE (IBD), BOTH CROHNS (CD) AND ULCERATIVE-COLITIS (UC)
    MCCANN, ML
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 91 (01) : 230 - 230
  • [28] Proteomic analysis distinctively separates Crohn's disease (CD) and ulcerative colitis (UC)
    Berndt, Uta
    Philipsen, Lars
    Bartsch, Sebastian
    Wiedenmann, Bertram
    Dignass, Axel
    Sturm, Andreas
    GASTROENTEROLOGY, 2006, 130 (04) : A357 - A358
  • [29] Long-term efficacy of AZAthioprine (aza) in inflammatory bowel disease (IBD) -: a European Multicenter study in 1200 patients with Crohn's disease (CD) and ulcerative colitis (UC)
    Holtmann, MH
    Krummenauer, F
    Claas, C
    Kremeyer, K
    Lorenz, D
    Rainer, O
    Vogel, I
    Galle, PR
    Boecker, U
    Boehm, S
    Büming, C
    Duchmann, R
    Gerken, G
    Herfarth, H
    Lingering, N
    Kruis, W
    Reinshagen, M
    Schmidt, J
    Stallmach, A
    Stein, J
    Sturm, A
    Hommes, D
    D'Haens, G
    Rutgeerts, P
    Neurath, M
    GASTROENTEROLOGY, 2005, 128 (04) : A13 - A13
  • [30] A Pooled Safety Analysis from the Ustekinumab Crohn's Disease and Psoriatic Diseases Phase 2 and 3 Clinical Trial Programs
    Sands, Bruce
    Ghosh, Subrata
    DeVilliers, Willem
    Ott, Elyssa
    Gasink, Chris
    Lang, Yinghua
    Szapary, Philippe
    Jacobstein, Doug
    Feagan, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S302 - S302
12345